TC
PLX icon

TFS Capital’s Protalix BioTherapeutics PLX Stock Holding History

TFS Capital’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,123
Closed -$32K – 1078
2015
Q4 		$32K Buy
+3,123
New +$31.8K ﹤0.01% 720
2015
Q2 		– Sell
-2,637
Closed -$47K – 1050
2015
Q1 		$47K Sell
2,637
-3,407
-56% -$66.7K ﹤0.01% 931
2014
Q4 		$111K Sell
6,044
-21,109
-78% -$453K 0.01% 904
2014
Q3 		$657K Buy
27,153
+25,607
+1,656% +$738K 0.06% 509
2014
Q2 		$56K Sell
1,546
-8
-0.5% -$323 ﹤0.01% 1074
2014
Q1 		$71K Sell
1,554
-1,176
-43% -$54.9K ﹤0.01% 1296
2013
Q4 		$106K Buy
+2,730
New +$115K 0.01% 1392

Other funds holding PLX

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

TFS Capital's PLX Position: Q1 2016 in Review

TFS Capital sold out of Protalix BioTherapeutics (PLX) in Q1 2016, closing a stake of 3,123 shares — an estimated $32K sold.

TFS Capital first reported a position in PLX in Q4 2013 and held it in 7 quarters. The position peaked at $657K in Q3 2014. 33 funds tracked by Wall St. Rank hold PLX as of Q1 2016.

  • TFS Capital reported no remaining Protalix BioTherapeutics position as of Q1 2016 after selling out during the quarter.
  • TFS Capital sold 3,123 Protalix BioTherapeutics shares in Q1 2016, an estimated $32K.
  • TFS Capital first reported a position in Protalix BioTherapeutics in Q4 2013 and held it in 7 quarters.
  • TFS Capital's Protalix BioTherapeutics position peaked at $657K in Q3 2014.
  • 33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2016.

Based on TFS Capital's 13F filing for Q1 2016, filed 10 May 2016.